Sotera Health's New CEO Sparks a 27% Rally as Raised Guidance and Cross-Business Synergies Take Center Stage
Q2 2026 results beat expectations, leverage hits target, and a fresh strategic focus points to accelerated growth.
SHC · Earnings Call · 2026-08-06
Leadership Transition and Strategy
On May 26, Alton Shader assumed the role of CEO at Sotera Health, and his first earnings call in August signaled continuity with a fresh emphasis on customer-centricity and cross-unit collaboration. Shader, who spent 25 years in healthcare, highlighted the company's essential role in delivering life-saving products and stressed the importance of cross-business unit synergies. cross business unit work is now a strategic priority, building on a foundation laid by former CEO Michael Petras. Shader noted, “These strengths position us well to deliver consistent and reliable growth, and this was evident in our second quarter results, as we delivered 8% constant currency revenue growth, 8.7% constant currency adjusted EBITDA growth and expanded our adjusted EBITDA margins compared to the second quarter of last year.” — Alton Shader, Chief Executive Officer · 2026-08-06 The stock has responded, posting a +27.4% return over the last 90 days, a clear vote of confidence in the new leadership and upbeat guidance.Segment Highlights: Sterigenics, Nordion, and Nelson Labs
All three segments delivered solid growth in Q2. Sterigenics grew 7% constant currency, driven by favorable pricing (4.3%) and improved volume/mix (2.7%), despite a tough comparable. Alton Shader emphasized the stability of demand, noting, “we're really pleased with the second quarter performance of Nelson Labs with the 5.4% constant currency growth.” — Alton Shader, Chief Executive Officer · 2026-08-06 Nelson Labs benefited from increased testing volumes and the clean room expansion, while Nordion's 16.7% growth was lifted by Cobalt-60 harvest timing. Segment income margins improved across Sterigenics and Nordion, with Nelson Labs' margin sequentially up 438 basis points, though still within its long-term range. The company also highlighted a major large customer conversion from in-sourcing to outsourcing, which will contribute in the back half. This opportunity was previously discussed, and the company now confirms it is tracking well.Balance Sheet and Capital Allocation
The balance sheet continues to strengthen. CFO Jon Lyons reported, “Our net leverage ratio further improved to 3x for the second quarter, marking an important milestone as we reached our long-term target leverage range of 2 to 3x.” — Jonathan Lyons, Chief Financial Officer · 2026-08-06 The company repriced its $1.4 billion term loan, lowering borrowing costs by 100 basis points in less than a year. Effective Net Cash is trending upward as the company de-leverages, consistent with management's commitment to disciplined capital allocation. CapEx will step up in 2026 to $200-225 million, largely for Sterigenics' EO facility upgrades and the new X-ray facility, which is now on track to generate revenue beginning in Q3. As Michael Petras noted in a prior call, “We're in qualification with our customers, just like any other facility that will have a ramp period over time. There will be a little impact in 2026, and then we'll start to see that accelerate in '27 and '28 and beyond.” — Michael Petras, Chief Executive Officer · 2026-02-24 This investment is part of a broader strategy to offer all sterilization modalities.Outlook and Litigation
Management raised its full-year 2026 guidance, now expecting constant currency revenue growth of 5.25%-6.75% and adjusted EBITDA growth of 5.75%-7.25%. The uptick in growth is expected to be led by Sterigenics, which has strong visibility into the back half. Litigation remains a watch item, but progress is being made: the New Mexico case was settled for an immaterial amount, and the Georgia appellate process continues, with a decision expected in spring/summer. Michael Petras commented,The California trials are slated for January or April 2027. With a strong Q2, a raised outlook, and a clear strategic direction under new leadership, Sotera Health appears well positioned to deliver on its promises.We're going through the appellate process right now. Obviously, our view is the court's rejection of the plaintiff's general causation, there is a critical issue common to all the cases, and we believe this underscores the lack of reliable scientific support.